SI-BONE, Inc. (SIBN)
SI-BONE, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Santa Clara, CA, US. The stock last traded at $18.67, down 0.69% on the session, giving a market capitalisation of $828.0M. On trailing twelve-month figures it carries a trailing P/E of -54.94, a net margin of -6.9%. Its beta of 0.67 implies it has historically moved less than the broad market.
SI-BONE, Inc. is a medical technology company that develops and markets specialized implantable solutions for musculoskeletal conditions affecting the sacropelvic region. These devices are utilized across the United States and internationally. Its flagship product, iFuse, is a minimally invasive surgical implant system designed to address a range of indications, including sacroiliac joint dysfunction and degeneration, adult spinal deformities, and traumatic fractures of the pelvic ring. Beyond iFuse, the company offers advanced iterations like iFuse-3D. This titanium implant retains the distinctive triangular cross-section of the original iFuse but incorporates a proprietary 3D-printed porous surface and a fenestrated design. Another offering is iFuse-TORQ, a series of 3D-printed threaded implants. These are specifically engineered for treating pelvic fractures and facilitating minimally invasive sacroiliac joint fusion procedures. SI-BONE distributes its products primarily through a dedicated direct sales force, complemented by a network of independent distributors. Established in 2008, the company maintains its corporate headquarters in Santa Clara, California.
SI-BONE, Inc. is most often compared with the following Healthcare names: